Deciphering the Antitussive, Expectorant, and Anti-Inflammatory Potentials of ShashamKyeongok-Go and Their Phytochemical Attributes: In Vivo Appraisal in ICR Mice

Jin-Ryul Hu 1, Chul-Jong Jung 2, Seong-Min Ku 2, Dae-Hwa Jung 3, Sae-Kwang Ku 1,4, Md. Mohibullah 5, Hae-Jeung Lee 6,* and Jae-Suk Choi 7,*

Abstract: In this paper, we hypothesized that ShashamKyeongok-go (SKOG) is a mixed preparation of Adenophorae Radix powder (AR) and Kyeongok-go (KOG). SKOG may be served as a novel preventive and/or therapeutic agent for various respiratory diseases. SKOG were orally administered to ICR mice at 400, 200, and 100 mg/kg once a day for 11 days to examine antitussive, expectorant, and anti-inflammatory effects. The NH₄OH exposure-induced allergic acute inflammation with coughing responses was dose-dependently and significantly ($p < 0.01$) inhibited by pretreatment with SKOG at doses of 400, 200, and 100 mg/kg. With these concentrations of SKOG, the thickness of intrapulmonary secondary bronchus mucosa and the number of periodic acid Schiff stain-positive mucous-producing cells were significantly ($p < 0.05$ or $p < 0.01$) increased, as a result of the increased amount of phenol red secretion. Subsequently, SKOG showed significant ($p < 0.01$) anti-inflammatory activities as characterized by reducing the effects of xylene-induced increases of ear weight, thickness of total ear and ear dermis, and number of infiltrated inflammatory cells in the ear dermis, in a dose-dependent manner. These results supported that SKOG might have potential therapeutic effects to be used as an antitussive, expectorant, and anti-inflammatory agents in the prevention or treatment of chronic bronchitis and asthma.

Keywords: shashamkyeongok-go; kyeongok-go; adenophorae radix; antitussive effects; expectorant effects; anti-inflammation

1. Introduction

Airways bronchitis and asthma are a chronic inflammatory disease occupied in the respiratory tract and possibly caused by inherited predisposition and long-term effects of environmental irritants such as dust mites, smoke, and various chemical irritants. Bronchoconstriction is one of the most frequent pathological events of having chronic bronchitis and asthma, where the airway tubes become narrower and harder, but which is supposed to be wider and smoother, in reaction to the introduced foreign particles [1]. Therefore, it affects patients with difficulty to breathe properly associated with cough induction. A
cough is defined as, voluntary or involuntary acts, a forced expulsion behavior to clear the throat, and breathing airways with a concomitant sound. In addition, it has two characteristic types including non-productive as dry and productive as chesty, which are exhaustive and adversely affect the quality of life [2]. It represents global public health problems which are likely to be enormously higher, more than 339 million people currently suffer from asthma [3]. Moreover, compelling evidence suggested that inflammatory processes in airways were implicated in developing the pathogenesis of many respiratory diseases [4,5]. Therefore, the present study is undertaken to search for new natural herb-based formulations acting as alternative therapeutics, which are rich in nature, deciphering the synergistic effects in antitussive, expectorant, and anti-inflammatory activities in patients with airways bronchitis and asthma complications.

*Adenophora triphylla* var. *japonica* Hara is under the genus of Adenophora (Campanulaceae), and has been documented as an oriental medicinal prescription in Korea, Japan, and China. Pharmacological potentials of *A. triphylla* are characterized by its antitussive, anti-inflammatory [6], and hepatoprotective properties [7,8]. Many of the pharmacological important compounds of dried root parts of *A. triphylla* are reported as triterpenoids, alkaloids, and various essential oil compounds including pyrrolidine and triphyllol [6], piperidine and heptacosane [9], lupenone [10,11], and saponine [12,13]. In addition, precedent research on the dried root parts of *A. triphylla*, alternatively known as Adenophorae Radix, have remarkable effects on in vitro mucus production [14], in vivo hepatoprotective [7], in vitro antitumor [12,13], and in vitro [8,10] and in vivo anti-obesity [8]. Kyeongok-go (KOG) is one of the widely accepted and most popular herbal recipes in oriental medicine of Korea, comprising of Rehmanniae Radix Crudus, Pulvis Hoelen, Ginseng Radix Alba, and honey [7,15]. Many experimental evidence showed the path of pharmacological importance of KOG by the researchers on antioxidant [15], anti-inflammatory [16], immunomodulatory [15], anti-fatigue and aerobic-capacity enhancing [16], and growth-promoting [17] potentials.

Therefore, we hypothesized and expected that the appropriate addition of Adenophorae Radix powders (AR) to KOG can potentiate antitussive, expectorant, and anti-inflammatory activities, which may be utilized as a novel tonic agent for preventing varied respiratory diseases. The present study was conducted in three different mouse models, such as NH4OH-induced coughing [18,19], phenol red secretion [18,20], and xylene-induced acute inflammation in the ear [21,22], to perform antitussive, expectorant, and anti-inflammatory assays, respectively. The obtained results from SKOG treatment groups were compared side-by-side with a single dose of AR, KOG and/or standard drugs of theobromine (TB), ambroxol (AM), and dexamethasone (DEXA), respectively [14,23], aiming at examining the synergistic effects of SKOG on the mitigation of chronic bronchitis and asthma.

2. Materials and Methods

2.1. Test Materials

Yellow-coloured and powdered forms of AR, KOG, and SKOG materials were supplied by Okchundang (Ulsan, Korea). To prepare KOG, briefly, appropriate amounts of individual herbs, namely Ginseng Radix Alba (6000 g), Pulvis Hoelen (12,000 g), Rehmanniae Radix Crudus (47,000 g), and honey (39,000 g), were mixed, heated at 60 °C for 72 h, and cooled at 20 °C; this process was repeated twice. To prepare SKOG, appropriate amounts of individual herbs, namely Ginseng Radix Alba (4500 g), Pulvis Hoelen (9000 g), AR (4500 g), Rehmanniae Radix Crudus (47,000 g), and honey (39,000 g) were mixed, heated in a water bath at 60 °C for 72 h, and cooled at 20 °C; this process was repeated twice (Table S1). Specimens of AR, KOG, and SKOG were deposited in the herbarium of the Medical Research Center, Daegu Haany University (Gyeongsan, Gyeongbuk, Korea) (code no. AR2016Ku01, KOG2016Ku01, and SKOG2016Ku01, respectively). Unless otherwise stated, all chemicals used in the study were purchased from Sigma-Aldrich LLC (St. Louis, MO, USA) and kept at 4 °C until use.
2.2. Analysis of Specific Ingredients of AR, KOG, and SKOG

2.2.1. Instrument and Reagents

An ultra-performance liquid chromatography (UPLC) system (Waters Corp., Milford, MA, USA) was used, where the photodiode array detector (PDA; Waters Corp.), Waters ACQUITY SM (Sample Manager) Autosampler, Waters ACQUITY CH-A Column Oven (20 °C), and C18 column with a dimension of 1.7 μm, 2.1 × 100 mm (ACQUITYTM BEH, Waters Corp.) were adjusted to the system [24]. The UPLC chromatogram was visualized using an Empower Software (Waters Corp.) equipped with the computer system. The sample extractor was an 8210R-DHT ultrasonicator (Branson Ultrasonics, Danbury, CT, USA). The HPLC grade extraction solvents were methanol (MeOH; Junsei Chemical Co., Ltd., Tokyo, Japan) and acetonitrile (BAKER, Center Valley, PA, USA). In case of the PDA analysis, the detection wavelength of lupeol, acteoside, catalposide, and 5H2F was fixed at 280 nm, and lobetyolin and syringaldehyde were analyzed in the wavelength of 310 and 254 nm, respectively [25].

2.2.2. Preparation of Standard Solutions

Appropriate amounts of AR components (lupeol, lobetyolin, and syringaldehyde), Reichmanniae Radix Crudus components (containing acteoside, catalposide, and 5-hydroxymethyl-2-furfural (5H2F)), and Ginseng Radix Alba component (ginsenoside Rg3 (Rg3)) were measured accurately and dissolved in dimethyl sulfoxide (DMSO) or MeOH to prepare standard stock solutions with a concentration of 1 μg/mL. Next, appropriate amounts of standard solutions were diluted in MeOH to prepare three different concentrations 1, 5, and 10 ng/mL. The standard curve of each compound was determined with a coefficient (R^2) value of more than 0.999. For standard preparations, lobetyolin was purchased from the Extrasynthese (Genay Cedex, France) and all the other standards were from Sigma-Aldrich LLC.

2.2.3. Preparation of Test Samples for UPLC Analysis

For the quantitative analysis, 1 g of the samples were added to 10 mL of 30% MeOH and then microwave extraction was performed for 1 h. The supernatant was filtered using a membrane filter paper of 0.2 μm in diameter. The filtered liquid was selected for UPLC analysis.

2.2.4. Phytochemical Quantification by UPLC

Lupeol, lobetyolin, syringaldehyde acteoside, catalposide, 5H3F, and Rg3 contents in AR, KOG, and SKOG were quantified using UPLC. The column was kept at 20 °C for the analysis. In the PDA analysis, lupeol, acteoside, catalposide, and 5H2F were analyzed at a wavelength of 280 nm, whereas lobetyolin and syringaldehyde were analyzed at 310 and 254 nm, respectively. The mobile phase was water and acetonitrile with formic acid (0.1%). Rg3 was analyzed at the wavelength of 203 nm and the mobile phase was a mixture of water and acetonitrile. A 2 μL of the sample was injected into UPLC with a flow rate of 0.4 mL/min. Phytochemicals of the injected sample were identified by the retention time and the same detectable wavelength value and quantified by measuring the area of the peak (Figure S1).

2.3. Antitussive Assay

2.3.1. Rodents and Husbandry

The Institute of Cancer Research (ICR) male mice, weighing 29–32 g upon received, were bought from OrientBio, Seungnum, Korea. Four mice were allocated to each cage and housed at the temperature of 20–25 °C and relative humidity of 50–55% in a controlled room of 12/12 h (light/dark) cycle, with free access to ad libitum of pelleted food (cat. no. 38057; Purinafeed, Seungnam, Korea) and water. After 7 days of adaptation, all the animals were selected for antitussive experiments, maintained as per the rules and regulations of national usage and welfare of laboratory animals based on ethical principles.
2.3.2. Treatment and Grouping

After a week of adaptation, the eligible rodents were randomly chosen and divided into 8 groups of 10 rodents each, including an intact vehicle control (distilled water (DW), orally administered at 10 mL/kg), NH$_4$OH control (DW and 25% NH$_4$OH-induced coughing treated groups), TB [14] (a reference control drug, oral administration at 10 mL/kg, corresponding to 50 mg/kg and 25% NH$_4$OH-treated groups), AR (oral administration at 10 mL/kg, corresponding to 400 mg/kg and 25% NH$_4$OH-treated groups), SKOG400 (oral administration at 10 mL/kg, corresponding to 400 mg/kg and 25% NH$_4$OH-treated groups), SKOG200 (oral administration at 10 mL/kg, corresponding to 200 mg/kg and 25% NH$_4$OH-treated groups), and SKOG100 (oral administration at 10 mL/kg, corresponding to 100 mg/kg and 25% NH$_4$OH-treated groups). SKOG was dissolved in DW to make working concentrations of 40, 20, and 10 mg/mL, and AR and KOG were prepared following the same procedure to make a concentration of 40 mg/mL for oral administration. Similarly, TB was suspended and prepared in DW to the working concentration of 5 mg/mL. All the treatments were performed once a day for 11 days before the NH$_4$OH exposure. To maintain the same restrain stress, DW was administered in all the control groups rather than AR, KOG, SKOG, or TB treatments.

2.3.3. Body Weight Measurement

Body weight (BW) changes in the treatment mice were measured once a day using an electronic balance (Precisa Instrument, Dietikon, Switzerland) during the entire administration period of AR, KOG, SKOG, or TB. The BW gain was calculated using a formula as follows:

The BW gain after 11 days of oral administration of test substances = BW at sacrifice—BW at the initial treatment of the test substance (g/head).

2.3.4. Coughing Induction and Monitoring

Coughing was induced by an inhalation of 25% NH$_4$OH (Sigma-Aldrich LLC), where 0.3 mL was taken to a 1 L Erlenmeyer flask and inhaled to mice for 45 s at 1 h after the last administration of the test substance. Following the NH$_4$OH induction, the number of coughing responses was quantitated in 6 min using video observations [21,22]. Mice with an intact vehicle control were exposed to 0.3 mL saline for 45 s, in replacement of NH$_4$OH. A cough in mice was characterized as opening the mouth with a sudden expulsion followed by the sound of coughing, contraction of thoracic and abdominal muscles, and shaking of the front body [20,21].

2.3.5. Histopathology

After obtaining video images, some portion of the left lateral lobes of individual lungs and trachea consisting of 3 mm from the thyroid cartilages were isolated and fixed in a solution of 10% neutral buffered formalin (NBF). The sample was then trimmed, embedded in paraffin, sectioned at 3–4 µm thickness, stained with hematoxylin and eosin (H&E) for general histopathology examination or with toluidine blue for mast cell examination, and observed under a light microscope (Eclipse 80i; Nikon, Tokyo, Japan). Histopathological profiles were analyzed with an image analysis program (iSolution FL ver 9.1; IMT i-solution Inc., Quebec, QC, Canada), as followed by the previously established methods [25,26].

2.4. Expectorant Assay

2.4.1. Rodents and Husbandry

ICR mice (♂) of 86 weeks old, weighing 29–32 g upon their receiveal, were bought from OrientBio, Seungnum, Korea. Animal husbandry was conducted the same as in the antitussive assay. Mice selected for expectorant experiments were maintained abiding by the rules and regulations of national usage and welfare of laboratory animals based on ethical principles.
2.4.2. Treatment and Grouping

After 7 days of adaptation, 70 mice each were selected and divided into 7 groups each, including an intact vehicle control (DW), AM (250 mg/kg administered mice), AR (administration at 400 mg/kg and AM-exposed group), KOG (administration at 400 mg/kg and AM-exposed group), SKOG (administration at 400 mg/kg and AM-exposed group), SKOG (administration at 200 mg/kg and AM-exposed group), SKOG (administration at 100 mg/kg and AM-exposed group). AR, KOG, and SKOG were orally administered the same as in the antitussive assay, once a day for 11 days before being treated with phenol red. To provide the same restrain stress, the intact vehicle control rodents were orally administered 10 mL/kg of DW, rather than AR, KOG, SKOG, or AM.

2.4.3. BW Measurement

The BW and BW gain were evaluated in a similar way as mentioned in the antitussive assay.

2.4.4. Measurement of Mucous Secretion

To measure the mucous secretion, rodents were intraperitoneally injected with a single dose of 5% phenol red solution (Junsei Chemical Co. Ltd., Tokyo, Japan) at 10 mL/kg dissolved in a saline solution (w/v), after 30 min of the last (eleventh) administration of test material. Gross images of individual mice were then obtained to investigate the phenol red-induced body-surface redness. Thereafter, the trachea was dissected after the sacrifice of mice by cervical dislocation and homogenized in normal saline for 15 min to prepare the trachea lavage fluid (TLF) after adding 1 mL of 5% NaHCO₃ solution (w/v). The optical density (OD) of TLF was recorded at the wavelength of 546 nm, as followed by the previous studies [20,22].

2.4.5. Histopathology

At trachea excisions, individual left lateral lobes of the lung were collected. Then, the lung lobes were fixed (10% NBF), crossly trimmed, embedded in paraffin, sectioned (3~4 µm thickness), stained (H&E) for general histopathology examination or with a Periodic acid Schiff stain for mucous-producing cell examination, and observed under a light microscope. Histopathological profiles were examined using an image analysis program, as described formerly [25–28].

2.5. Anti-Inflammatory Assay

2.5.1. Rodents and Husbandry

ICR mice (♂) of 96 weeks old, weighing 29–32 g upon their receival, were bought from OrientBio, Seungnum, Korea. Animal husbandry was conducted the same as in the antitussive assay. Mice selected for anti-inflammatory experiments were maintained following the rules and regulations of national usage and welfare of laboratory animals based on ethical principles.

2.5.2. Treatment and Grouping

After 7 days of adaptation, 80 mice each were selected and divided into 8 groups each, including an intact vehicle control (DW), xylene control (0.03 mL of xylene of topical application to the anterior surface of the right ear), DEXA (administration at 1 mg/kg and Xylene-exposed group), AR (administration at 400 mg/kg and xylene-exposed group), KOG (administration at 400 mg/kg and xylene-exposed group), SKOG (administration at 400 mg/kg and xylene-exposed group), SKOG (administration at 200 mg/kg and xylene-exposed group), SKOG (administration at 100 mg/kg and xylene-exposed group). AR, KOG, and SKOG were orally administered the same as in the antitussive and expectorant experiments, once a day for 11 days before the xylene treatment. To provide the same restrain stress, the intact vehicle control rodents were orally administered at 10 mL/kg of DW, rather than AR, KOG, SKOG, or xylene.
2.5.3. BW Measurement

BW and BW gain were determined in the same procedure as mentioned in the antitussive assays.

2.5.4. Ear Weight Measurement

After the xylene treatment for 2 h, circular sections of the ear were collected and weighed as the absolute ear wet-weight. The relative ear weight (% of BW) was measured to reduce the differences of individuals using a formula as given below:

\[
\text{Relative ear weight (% of BW)} = \left( \frac{\text{absolute ear wet-weight}}{\text{BW at sacrifice}} \right) \times 100
\]

2.5.5. Histopathology

Individual ear samples were fixed in 10% NBF, crossly trimmed, embedded in paraffin, sectioned (to 3–4 µm thickness), and stained (H&E) for general histopathology examination or with toluidine blue for mast cell examination. Histopathological profiles were analyzed with an image analysis software program, as described in previous studies [23,25,26,29].

2.6. Statistical Analyses

All data were shown as the mean ± standard deviation (SD) of six measurements, whereas data related to the rodent experiments were eight mice in each experiment. All the statistical analyses were performed by Statistical Package for the Social Sciences (SPSS) (14.0K; IBM SPSS Inc., Armonk, NY, USA), where the statistical difference was \( p \)-value of <0.05, followed by the methods of Hu et al. [14].

3. Results

3.1. Contents of Specific Compounds of SKOG

Lobetinol, lupeol, and syringaldehyde were detected in AR at 6.99 ± 0.24, 2029.00 ± 1.96, and 0.26 ± 0.03 mg/kg of fresh weight (FW), respectively. 5H2F, acteoside, catalposide, and Rg3 were detected in KOG at 628.26 ± 13.2, 0.33 ± 0.02, 0.41 ± 0.03, and 7.27 ± 0.46 mg/kg (FW), respectively. Lupeol, syringaldehyde, 5H2F, acteoside, catalposide, and Rg3 were detected in SKOG at 224.52 ± 12.5, 0.14 ± 0.01, 559.50 ± 1.70, 0.31 ± 0.01, 0.33 ± 0.01, and 4.42 ± 0.02 mg/kg (FW), respectively. These results were obtained from the UPLC analysis, as presented in Figure S1.

3.2. Antitussive Assay

3.2.1. Changes in BW and BW Gain

Following the oral administration, the NH\(_4\)OH control mice had no effects on BW and BW gain as compared with those rodents of the intact vehicle control group. Similarly, AR and KOG 400 mg/kg, TB 50 mg/kg, and SKOG 400, 200, and 100 mg/kg observed no significant changes in BW and BW gain when compared with the NH\(_4\)OH control mice, respectively. The results of BW and BW gain in the rodents treated with SKOG 400, 200, and 100 mg/kg were non-significant, compared with the AR and KOG 400 mg/kg groups (Table A1).

3.2.2. Changes in the Coughing Frequency

Due to the exposure of NH\(_4\)OH in mice, the number of coughing responses was significantly increased when compared with the intact vehicle control mice (\( p < 0.01 \)). However, dose-dependent and significant decreases (\( p < 0.01 \)) in the number of coughing responses were seen with mice treated with SKOG 400, 200, and 100 mg/kg as compared to the NH\(_4\)OH control mice. Similar results were found in the treatment of a group of AR and KOG 400 mg/kg and TB 50 mg/kg showing a significant decrease (\( p < 0.01 \)) in coughing responses, compared with the NH\(_4\)OH control mice. Moreover, decreased numbers of the coughing response were significantly (\( p < 0.01 \)) higher in SKOG 400 and 200 mg/kg treatment groups than those of mice treated with AR and KOG 400 mg/kg. Other findings revealed that AR and KOG 400 mg/kg and SKOG 100 mg/kg treatment were found to be
similar or more favorable to the effects of TB 50 mg/kg against NH$_4$OH-induced coughing responses (Figure 1).

Figure 1. Effects of adenophorae radix powder (AR), kyeongok-go (KOG), and shashamkyeongok-go (SKOG) on the changes of coughing frequencies in NH$_4$OH-induced coughing mice. Values are expressed as the mean ± SD of 10 mice. Different letters indicate statistical significance. Treatment groups expressed as $^a$ $p < 0.01$, $^b$ $p < 0.01$, $^c$ $p < 0.01$, and $^d$ $p < 0.01$ compared with the intact vehicle control, NH$_4$OH control, AR 400 mg/kg, and KOG 400 mg/kg by the Mann-Whitney U (MW) test, respectively.

3.2.3. Histopathological Findings of the Trachea and Lung

Significant decreases ($p < 0.01$) in the tracheal lumen diameter and ASA, as well as increases in the thickness of the total tracheal wall, epithelium, and submucosa; the number of infiltrated inflammatory and mast cells in the trachea; thicknesses of the alveolar septum; and the number of inflammatory cells between the alveolar septum were observed in NH$_4$OH treated mice. However, these NH$_4$OH-induced allergic acute inflammation-related histopathological findings were significantly inhibited ($p < 0.01$) by the pre-treatment of SKOG 400, 200, and 100 mg/kg in a dose-dependent manner, compared with those in the NH$_4$OH-induced control rodents. In addition, the mice treated with AR and KOG 400 mg/kg and TB 50 mg/kg significantly reduced ($p < 0.01$) the NH$_4$OH-induced allergic acute inflammation in histopathological observations, compared with those in the NH$_4$OH-induced control rodents. Especially, the mice treated with SKOG 400 and 200 mg/kg significantly ($p < 0.01$ or $p < 0.05$) decreased the NH$_4$OH-induced allergic acute inflammation, compared with those in the mice fed with AR and KOG 400 mg/kg. Moreover, SKOG 100 mg/kg showed favorable inhibitory effects similar to those of AR and KOG 400 mg/kg on NH$_4$OH-induced allergic acute inflammation. In addition, AR and KOG 400 mg/kg and SKOG 100 mg/kg observed inhibitory effects similar to or more favorable than those of TB 50 mg/kg on NH$_4$OH-treated groups (Tables 1 and 2, Figures 2 and 3).
Table 1. Effects of AR, KOG, and SKOG on the histomorphometry of trachea in mice.

| Index Groups | Diameter of Lumen (µm) | Thickness (µm) | Cells (Numbers/mm²) |
|--------------|------------------------|----------------|---------------------|
|              |                        | Total Wall | Epithelium | Submucosa | Inflammatory | Mast |
| Controls     |                        |            |            |           |              |      |
| Intact       | 1177.86 ± 130.95       | 161.47 ± 15.34 | 14.38 ± 2.91 | 26.68 ± 4.85 | 21.40 ± 12.21 | 1.20 ± 0.79 |
| NH₄OH        | 658.57 ± 106.44        | 220.38 ± 13.45 b | 37.53 ± 9.48 b | 89.73 ± 10.46 b | 449.30 ± 102.75 b | 38.70 ± 11.66 b |
| Reference    |                        |            |            |           |              |      |
| TB 50 mg/kg  | 860.11 ± 100.75        | 191.23 ± 10.24 bi | 24.21 ± 4.36 bi | 47.31 ± 11.39 bi | 167.40 ± 40.26 bi | 14.30 ± 4.60 bi |
| AR 400 mg/kg | 934.14 ± 104.43        | 185.59 ± 10.94 bi | 23.07 ± 3.32 bi | 44.99 ± 6.09 bi | 62.70 ± 37.57 bi | 8.60 ± 2.27 bi |
| KOG 400 mg/kg| 934.89 ± 83.13         | 186.21 ± 11.10 bi | 23.87 ± 2.38 bi | 40.31 ± 6.64 bi | 184.10 ± 20.32 bi | 8.40 ± 1.51 bi |
| SKOG 400 mg/kg|                     |            |            |           |              |      |
| 400 mg/kg    | 1087.76 ± 118.72       | 171.56 ± 7.07  hikm | 18.92 ± 2.14  hikm | 30.30 ± 3.24  hikm | 85.50 ± 19.82  hikm | 1.80 ± 1.03  hikm |
| 200 mg/kg    | 1036.55 ± 76.64        | 175.45 ± 5.03  hikm | 19.74 ± 1.37  hikm | 32.71 ± 3.79  hikm | 120.70 ± 20.94  hikm | 3.70 ± 1.34  hikm |
| 100 mg/kg    | 936.74 ± 70.89         | 185.19 ± 7.57  hikm | 23.76 ± 3.34  hikm | 42.41 ± 8.60  hikm | 177.60 ± 26.02  hikm | 8.70 ± 2.16  hikm |

Values are presented as the mean ± SD of 10 mice. Different letters indicate statistical significance. Treatment groups expressed as * p < 0.01 and b p < 0.05, c p < 0.01, d p < 0.01 and * p < 0.05, and f p < 0.01 and g p < 0.05 compared with the intact control, NH₄OH control, AR 400 mg/kg, and KOG 400 mg/kg by the least-significant differences multi-comparison (LSD) test, respectively. Moreover, treatment groups showed b p < 0.01, c p < 0.01, d p < 0.01 and f p < 0.01 compared with the intact control, NH₄OH control, AR 400 mg/kg, and KOG 400 mg/kg by the MW test, respectively.

Table 2. Effects of AR, KOG, and SKOG on the histomorphometry of lung—alveolar regions in mice.

| Index Groups | Alveolar Surface Area (%) | Septum Thickness (µm) | Inflammatory Cells (Numbers/mm²) |
|--------------|---------------------------|-----------------------|----------------------------------|
|              |                           | Total Wall | Epithelium | Submucosa | Inflammatory | Mast |
| Controls     |                           |            |            |           |              |      |
| Intact       | 78.87 ± 9.31              | 7.32 ± 1.45 | 72.41 ± 10.80  f | 1886.70 ± 394.17  f | 60.20 ± 19.63 |
| NH₄OH        | 30.94 ± 9.58 a             |            |            |           |              |      |
| Reference    |                           |            |            |           |              |      |
| TB 50 mg/kg  | 51.13 ± 5.95 ac            | 30.53 ± 10.06  rh | 27.22 ± 7.28  rh | 492.00 ± 114.18  rh | 453.80 ± 104.35  rh |
| AR 400 mg/kg | 53.83 ± 7.88 ac            | 27.98 ± 3.75  rh | 492.60 ± 118.49  rh | 180.20 ± 26.02  rh | 8.70 ± 2.16  rh |
| KOG 400 mg/kg| 52.34 ± 8.24 ac            |            |            |           |              |      |
| SKOG 400 mg/kg|                     |            |            |           |              |      |
| 400 mg/kg    | 71.32 ± 5.65 bcdff         | 12.56 ± 2.52  ghik | 234.20 ± 42.55  ghik | 347.60 ± 79.19  ghik | 841.90 ± 132.69  ghik |
| 200 mg/kg    | 62.29 ± 6.45 aedf          | 20.26 ± 3.12  ghik | 347.60 ± 79.19  ghik | 841.90 ± 132.69  ghik | 841.90 ± 132.69  ghik |
| 100 mg/kg    | 53.36 ± 9.65 ac            | 27.99 ± 6.85  ghik |                                |                     |      |

Values are presented as the mean ± SD of 10 mice. Different letters indicate statistical significance. Treatment groups expressed as * p < 0.01 and b p < 0.05, c p < 0.01, d p < 0.01 and * p < 0.05, and f p < 0.01 compared with the intact control, NH₄OH control, AR 400 mg/kg, and KOG 400 mg/kg by the LSD test, respectively. Moreover, treatment groups showed b p < 0.01, c p < 0.01, d p < 0.01 and f p < 0.01 compared with the intact control, NH₄OH control, AR 400 mg/kg, and KOG 400 mg/kg by the MW test, respectively.
Figure 2. Changes in the histological features of trachea in mice. Different treatment groups as followed by the (A) intact vehicle control, (B) NH₄OH control, (C) TB 50 mg/kg + NH₄OH, (D) AR 400 mg/kg + NH₄OH, (E) KOG 400 mg/kg + NH₄OH, (F) SKOG 400 mg/kg + NH₄OH, (G) SKOG 200 mg/kg + NH₄OH, and (H) SKOG 100 mg/kg + NH₄OH. Scale bar = 120 µm. LU: Lumen; CA: Cartilages; SM: Submucosa; EP: Epithelium.
Figure 3. Changes in the histological features of lung in mice. Different treatment groups as followed by the (A) intact vehicle control, (B) NH$_4$OH control, (C) TB 50 mg/kg + NH$_4$OH, (D) AR 400 mg/kg + NH$_4$OH, (E) KOG 400 mg/kg + NH$_4$OH, (F) SKOG 400 mg/kg + NH$_4$OH, (G) SKOG 200 mg/kg + NH$_4$OH, and (H) SKOG 100 mg/kg + NH$_4$OH. Scale bar = 120 µm. SB: Secondary bronchus; TA: Alveolus-terminal bronchiole; TB: Theobromine; ASA: Alveolar surface area; BR: Bronchus.

3.3. Expectorant Assay
3.3.1. Changes in BW and BW Gain

Following 11 days of oral administration, the results of BW and BW gain showed no significant changes in different treatment groups of AM 250 mg/kg, AR and KOG 400 mg/kg, SKOG 400, 200, and 100 mg/kg when compared with the intact vehicle control mice, respectively. Similarly, rodents treated with SKOG 400, 200, and 100 mg/kg had no significant difference in BW and BW gain, respectively, compared with AR and KOG 400 mg/kg (Table A2).
3.3.2. Body-Surface Gross Findings

An experiment was set to elucidate the expectorant effect of SKOG 400, 200, and 100 mg/kg that showed noticeable and dose-dependent increases of body surface redness, compared with the intact vehicle control rodents, which indicates an increased uptake and secretion of intraperitoneally injected phenol red. Moreover, AR and KOG mg/kg and AM 250 mg/kg dramatically increased the secretion of phenol red after 30 min of intraperitoneal injection as compared with the intact vehicle control. Of note, SKOG 400 and 200 mg/kg had obvious increases of phenol red secretion with a gross sign of body surface redness, while the treatment with AR and KOG 400 mg/kg, and the results were more similar to or favorable than those of AM 250 mg/kg fed rodents (Figure S2).

3.3.3. Changes in Mucous Secretion

Mice treated with AR and KOG 400 mg/kg, AM 250 mg/kg, and SKOG 400, 200, and 100 mg/kg showed dose-dependent and significant increases \( (p < 0.01) \) in the OD values of TLF, compared with the intact vehicle control rodents after 30 min of phenol red injection, which indicated an increase in the mucous secretion in the trachea. Moreover, SKOG 400 and 200 mg/kg significantly exhibited \( (p < 0.01) \) OD values of TLF as compared with AR and KOG 400 mg/kg, respectively, and the results were similar to or more favorable than those rodents fed with AM 250 mg/kg (Figure 4).

![Figure 4](image_url)

**Figure 4.** Effects of AR, KOG, and SKOG on mucous secretions in the trachea of mice. Values are shown as the mean ± SD of 10 mice. Different letters indicate statistical significance. Treatment groups expressed as \( ^a p < 0.01, ^b p < 0.01, \) and \( ^c p < 0.01 \) compared with the intact vehicle control, AR 400 mg/kg, and KOG 400 mg/kg by the LSD test, respectively.

3.3.4. Histopathological Findings in the Intrapulmonary Secondary Bronchus

The administration of mice with SKOG 400, 200, and 100 mg/kg resulted in a dose-dependent and significant increase \( (p < 0.01 \) or \( p < 0.05) \) in the thickness of intrapulmonary secondary bronchus mucosa and the number of PAS-positive mucous-producing cells, respectively, compared with those mice in the vehicle control, suggesting an ability to increase the mucous secretion and activity of bronchus mucosa. Moreover, AR and KOG 400 mg/kg and AM 250 mg/kg administered mice showed similar significant \( (p < 0.01) \) effects as compared with the intact vehicle control. Compared with AR and KOG 400 mg/kg, mice with SKOG 400 and 200 mg/kg treatment groups showed a significant increase of thickness of intrapulmonary secondary bronchus mucosa and the number of PAS-positive
mucous-producing cells, respectively. The results were similar to or more favorable than the mice with the treatment of AM 250 mg/kg (Figures 5 and 6).

Figure 5. Changes in the histological features of intrapulmonary secondary bronchus in mice. Different treatment groups as followed by the (A) intact vehicle control, (B) AM 250 mg/kg, (C) AR 400 mg/kg, (D) KOG 400 mg/kg, (E) SKOG 400 mg/kg, (F) SKOG 200 mg/kg, (G) SKOG 100 mg/kg. Scale bar = 60 μm. AM: Ambroxol; EP: Epithelium; LU: Lumen; PAS: Periodic Acid Schiff Stain.
Figure 6. Effects of AR, KOG, and SKOG on the intrapulmonary secondary bronchus epithelial thicknesses and PAS-positive mucous producing cell numbers in mice. Values are presented as the mean ± SD of 10 mice. Different letters indicate statistical significance. Treatment groups expressed as \( \text{a} p < 0.01 \) and \( \text{d} p < 0.01 \), \( \text{b} p < 0.01 \) and \( \text{e} p < 0.01 \), and \( \text{c} p < 0.01 \) and \( \text{f} p < 0.01 \) compared with the intact vehicle control, AR 400 mg/kg, and KOG 400 mg/kg by the LSD and MW tests, respectively.

3.4. Anti-Inflammatory Assay

3.4.1. Changes in BW and BW Gain

Following 11 days of oral feeding, mice treated with SKOG 400, 200, 100 mg/kg as well as AR and KOG 400 did not show any significant changes in BW and BW gain, compared with intact vehicle and xylene controls, respectively. However, the DEXA 1 treated mice showed significant (\( p < 0.01 \) or \( p < 0.05 \)) decreases in BW after 2 days of administration and BW gain during 11 days of the feeding, compared with intact vehicle control and xylene control rodents, respectively (Table A3).

3.4.2. Ear Gross-Findings

Ear redness and swelling caused by the topical application of xylene were remarkably inhibited in rodents fed with AR and KOG 400 mg/kg, DEXA 1 mg/kg, and SKOG 400, 200, and 100 mg/kg in a dose-dependent manner, respectively, compared with the xylene control mice. Among the treatments, SKOG 400 and 200 mg/kg exhibited clear decreases in ear redness and edema, compared with those rodents that received AR and KOG doses at 400 mg/kg, respectively. Additionally, SKOG 100 mg/kg observed similar xylene-induced ear redness and edema gross signs, compared with those of AR and KOG 400 mg/kg, respectively. Moreover, SKOG 400 mg/kg showed favorable decreases in ear redness and edema, compared with those of DEXA 1 mg/kg, but AR and KOG 400 mg/kg as well as SKOG 200 and 100 mg/kg showed slight inhibitory effects on the xylene-induced ear redness and edema, compared with those of DEXA 1 mg/kg, in the current gross observation (Figure S3).

3.4.3. Changes in Ear Weight

A topical application of xylene to rodents resulted in significant increases (\( p < 0.01 \)) in the absolute and relative ear weights which were significantly (\( p < 0.01 \)) and dose-
dependently decreased in rodents when administering with AR and KOG 400 mg/kg, DEXA 1 mg/kg, and SKOG 400, 200, and 100 mg/kg, respectively, compared with the xylene control mice. Among the treatment groups, SKOG 400 and 200 mg/kg showed significant \((p < 0.01\) or \(p < 0.05\)) decreases in ear weights, compared with those rodents receiving the doses of AR and KOG 400 mg/kg. Of note, SKOG 400 mg/kg exhibited more favorable inhibitory activities on xylene-induced increases in absolute and relative ear weights in mice than that of the DEXA 1 mg/kg treated group (Figure 7).

3.4.4. Histopathological Findings on the Ear

Significant increases \((p < 0.01)\) in the thickness of total ear and ear dermis, number of inflammatory cells on the ear dermis, degranulation-related decreases in the number of mast cells in the dermis, and decreases in collagen fiber-occupied regions in the dermis, as well as no significant changes in the ear epidermis thickness, were observed in the mice with xylene control. However, these xylene-induced ear acute contact dermatitis-related findings, as observed in the histopathological inspection, were significantly inhibited \((p < 0.01)\) by SKOG feeding at doses of 400, 200, and 100 mg/kg, compared with those in the xylene control mice. In addition, AR and KOG 400 mg/kg and DEXA 1 mg/kg had shown a similar significant inhibition \((p < 0.01)\) on xylene-induced ear acute contact dermatitis-related histopathology, compared with xylene control mice. Especially, SKOG 400 and 200 mg/kg observed significantly increased \((p < 0.01)\) inhibitory effects on xylene-treated rodents, compared with those of AR and KOG 400 mg/kg. Additionally, SKOG 400 mg/kg exerted favorable inhibitory effects on xylene, which were comparable to the effects of DEXA 1 mg/kg. However, AR and KOG 400 mg/kg, SKOG 200 mg/kg, and SKOG 100 mg/kg showed lower inhibitory effects on xylene than those rodents fed with DEXA 1 mg/kg (Table 3, Figure 8).
Table 3. Effects of AR, KOG, and SKOG on the histomorphometry of ear in mice.

| Index Groups | Thickness (µm) | Cells (Numbers/mm²) | Collagen Fiber (%/mm² of Dermis) |
|--------------|----------------|---------------------|----------------------------------|
|              | Total          | Epidermis           | Dermis                           | Inflammatory | Mast      |                                                |
| Controls     |                |                     |                                  |              |          |                                                |
| Intact       | 103.41 ± 11.47 | 8.98 ± 0.93         | 54.86 ± 11.97                   | 15.20 ± 4.66 | 69.00 ± 15.48 | 78.31 ± 9.75 |
| Xylene       | 264.48 ± 30.02 f | 9.07 ± 1.16          | 132.28 ± 22.16 f               | 263.40 ± 55.50 f | 8.20 ± 4.16 a | 26.74 ± 6.58 f |
| Reference    |                |                     |                                  |              |          |                                                |
| DEXA 1 mg/kg | 99.55 ± 9.57 h | 8.50 ± 1.65         | 52.88 ± 13.72 h                | 18.10 ± 10.54 h | 61.30 ± 12.65 c | 77.43 ± 12.79 h |
| AR 400 mg/kg | 166.51 ± 17.59 fh | 8.77 ± 0.71        | 75.41 ± 8.63 fh               | 72.30 ± 14.17 fh | 45.20 ± 10.52 ac | 64.73 ± 10.85 fh |
| KOG 400 mg/kg| 158.83 ± 13.35 fh | 8.76 ± 0.82       | 71.55 ± 5.05 fh               | 69.00 ± 12.00 fh | 42.40 ± 6.72 ac | 67.59 ± 4.70 fh |
| SKOG 400 mg/kg|                |                     |                                  |              |          |                                                |
| 400 mg/kg    | 105.94 ± 13.74 hj | 9.15 ± 1.09        | 51.58 ± 6.97 hj               | 29.20 ± 8.26 hj | 61.00 ± 10.92 cde | 81.51 ± 7.58 hj |
| 200 mg/kg    | 128.25 ± 15.08 hj | 8.29 ± 1.18        | 61.37 ± 6.03 hj               | 48.40 ± 14.21 hj | 58.20 ± 8.53 bde | 76.84 ± 5.22 hj |
| 100 mg/kg    | 160.57 ± 18.68 fh | 8.73 ± 0.92        | 71.69 ± 10.31 fh               | 77.70 ± 21.76 fh | 42.80 ± 10.09 ac | 66.43 ± 10.37 fh |

Values are expressed as the mean ± SD of 10 mice. Different letters indicate statistical significance. Treatment groups expressed as *p < 0.01 and b p < 0.05, c p < 0.01, d p < 0.01, and e p < 0.01 compared with the intact control, xylene control, AR 400 mg/kg, and KOG 400 mg/kg by the LSD test, respectively. Moreover, treatment groups showed f p < 0.01 and g p < 0.01, h p < 0.01, i p < 0.01, j p < 0.01 compared with the intact control, xylene control, AR 400 mg/kg, and KOG 400 mg/kg by the MW test, respectively.

Figure 8. Changes in the histological features of ear in mice. Different treatment groups as followed by the (A) intact vehicle control, (B) xylene control, (C) DEXA 1 mg/kg + xylene, (D) AR 400 mg/kg + xylene, (E) KOG 400 mg/kg + xylene, (F) SKOG 400 mg/kg + xylene, (G) SKOG 200 mg/kg + xylene, and (H) SKOG 100 mg/kg + xylene. Scale bar = 120 µm. AS: Anterior Surface; CA: Cartilage; DE: Dermis; EP: Epidermis.
4. Discussion

The phytochemical observation on SKOG signified its medicinal value by the presence of various pharmacological important bioactive compounds, which was identified and quantified by the UPLC analysis. SKOG was mainly composed of lupeol, syringaldehyde, 5H2F, acteoside, catalposide, and Rg3 compounds, which were a direct or indirect link to the current activities of SKOG. It has been extensively documented that the following identified compounds are believed to be a potential source of bioactivities such as an anti-inflammatory and anti-cancer activities of lupeol [30]; antioxidant and antimicrobial activities of syringaldehyde [31]; antioxidative, anti-hypoxic, anti-allergic, anti-sickling, anti-inflammatory, and anti-hyperuricemic effects of 5H2F [32]; antioxidant and antihypertensive activities of acteoside [33]; preventing mucosal inflammation of catalposide [34]; ameliorating cancer, lung injury, depression, and diabetes of Rg3 [35].

During the 11-day treatment with different test substances, all the mice in three different models such as antitussive, expectorant, and anti-inflammatory assays showed a normal BW and BW gain that fell in the range of age-matched, normal reference mice [36], except for the xylene-induced acute inflammation rodents fed with DEXA 1 mg/kg. In addition, compared with those in the rodents fed with AR and KOG 400 mg/kg, no significant changes in BW and BW gain were shown in the rodents fed with SKOG 400, 200, and 100 mg/kg in all the three different assays. The xylene-induced acute inflammation mice treated with DEXA 1 mg/kg showed significant decreases in BW from 2 days after the initial feeding and in BW gain during the treatment period, when compared with the intact vehicle and xylene control animals. A decrease in BW after the treatment with DEXA has been detected as a major side effect of DEXA in other animal studies of anti-inflammatory effects [26,37].

The NH4OH has been a well-known antitussive agent to induce the coughing frequency with characteristic acute inflammation in airways [25,26]. The mouse model of NH4OH exposure-induced coughing was used to confirm whether the antitussive effects of KOG were potentiated by the appropriate addition of AR. ASA is directly related to the gas exchange capacity of the lung; a higher ASA means a higher gas exchange capacity [26,27,38]. In the antitussive experiment, the NH4OH-induced allergic acute inflammation with coughing responses and decreased ASA were dose dependently and significantly inhibited by the feeding of SKOG at doses of 400, 200, and 100 mg/kg. These findings are considered a piece of direct evidence that the appropriate addition of AR to KOG synergistically increased the antitussive activities, at least in the conditions of the current study.

Expectorant agents have the ability to increase the hydration of secretions so that the irritating respiratory tract becomes lubricated [14]. Therefore, the ability to increase the muscus secretion can be an effective approach to search for a potential drug. Here, the phenol red solution was used to identify whether the expectorant effects of KOG in mice were synergistically potentiated by the appropriate addition of AR. Later, the PAS staining method was performed to evaluate the mucous intensity and number of mucous-producing cells [28,39,40]. The result of the study was found to be effective in the effects of SKOG, which showed a significant and dose-dependent expectorant ability in oral administered mice, through enhanced mucous secretion and promoted functional activities of trachea and bronchus mucosa [21–23]. These findings are considered obvious evidence that the appropriate addition of AR synergistically increased the expectorant activities of KOG.

An investigation on the anti-inflammatory efficacy of the test substances can easily be achieved following the application of xylene on the anterior surface of the mouse ear to induce acute inflammation in the mouse ear model [14]. In the present study, KOG was investigated by whether the appropriate addition of AR could subsequently promote anti-inflammatory potentials, in addition to antitussive and expectorant activities. The xylene control mice are reported to have noticeable changes in the gross sign and weight of the ear with characteristic inflammatory-related histopathological features [25,26]. Following the administration, SKOG at doses of 400 and 200 mg/kg significantly increased the anti-
inflammatory effects, compared to those in the mice administered with AR and KOG 400 mg/kg on xylene-induced acute inflammation in the rodent ear. In addition, SKOG 400 mg/kg showed anti-inflammatory effects comparable to those of DEXA 1 mg/kg on xylene-induced acute inflammation in the rodent ear. These findings are considered direct and clear evidence that the appropriate addition of AR synergistically increased the anti-inflammatory activities of KOG, at least in the conditions of the current study. However, further research is warranted as to whether SKOG has some other effective bioactive compound(s) and whether their molecular mechanism of actions is responsible for the synergistic effects in the current study. Similarly, changes in the relative lung weight could have been measured to ensure that there are no significant changes due to the treatments and that also needs to be addressed in further studies.

5. Conclusions

In conclusion, our study suggested that the appropriate addition of AR to KOG in order to prepare the SKOG recipe exhibited significant and synergistic effects in antitussive, expectorant, and anti-inflammatory activities by potentiating the modulation of the activities of respiratory mucous-producing cells and mast cells in animal models. The most effective doses of SKOG were found to be 400 and 200 mg/kg, compared to those in the mice fed with AR and KOG 400 mg/kg, suggesting that an effective portion of bioactive compounds is present at these doses. These findings were considered as pharmacological shreds of evidence for the traditional use of AR and KOG as antitussive, expectorant, and anti-inflammatory remedies. Therefore, it is expected that SKOG may serve as a preventive or therapeutic agent in varied respiratory diseases, particularly those caused by environmental toxicants.

Supplementary Materials: The following are available online at https://www.mdpi.com/2076-3417/11/3/1349/s1, Figure S1: UPLC analysis of identification and quantification of lupeol, syringaldehyde, SH2F, acteoside, catalposide, and Rg3 ingredients in SKOG, a mixture of AR and KOG. (A) standard for AR, (B) Test AR, (C) standard for KOG, (D) Test KOG, (E) standard for SKOG, and (F) Test SKOG., Table S1: Composition of KOG and SKOG used in this study.

Author Contributions: Conceptualization, S.-K.K. and J.-S.C.; methodology, J.-R.H. and S.-K.K.; validation, D.-H.J., M.M., and S.-K.K.; formal analysis, S.-M.K., S.-K.K. and H.-J.L.; investigation, S.-M.K., D.-H.J. and S.-K.K.; resources, C.-J.J. and S.-K.K.; data curation, S.-K.K. and D.-H.J.; writing—original draft preparation, S.-K.K. and H.-J.L.; writing—review and editing, M.M. and J.-S.C.; visualization, J.-R.H. and S.-K.K.; supervision, S.-K.K., H.-J.L., and J.-S.C.; project administration, D.-H.J. and S.-K.K.; funding acquisition, S.-K.K. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Research Foundation of Korea grant, funded by the Korea government (MSIT) (no. 2018R1A5A2025272).

Institutional Review Board Statement: Antitussive, expectorant and anti-inflammatory experiments in this study were approved by the Institutional Animal Care and Use Committee of Daegu Haany University. The approval numbers were DHU2016-034, DHU2016-035 and DHU2016-036, respectively.

Data Availability Statement: Data supporting reported results can be made available on demand.

Conflicts of Interest: The authors declare no conflict of interest.
### Appendix A

#### Table A1. Changes on the body weight gains in antitussive assay.

| Groups    | Body Weights (g) at Test Material Administration | Body Weight Gains (g) [B – A] |
|-----------|--------------------------------------------------|-----------------------------|
|           | First [A]                                        | Last [B]                    |                             |
| Controls  |                                                   |                             |                             |
| Intact    | 29.34 ± 1.29                                     | 30.98 ± 1.39                | 1.64 ± 0.74                 |
| NH₄OH     | 29.44 ± 1.65                                     | 31.11 ± 2.22                | 1.67 ± 0.84                 |
| Reference |                                                   |                             |                             |
| TB 50 mg/kg| 29.23 ± 1.49                                     | 30.94 ± 1.77                | 1.71 ± 0.97                 |
| AR 400 mg/kg| 29.41 ± 0.96                                     | 31.12 ± 1.74                | 1.71 ± 1.18                 |
| KOG 400 mg/kg| 29.58 ± 1.24                                    | 31.10 ± 1.56                | 1.52 ± 0.61                 |
| SKOG      |                                                   |                             |                             |
| 400 mg/kg | 29.66 ± 1.07                                     | 31.35 ± 1.34                | 1.69 ± 0.70                 |
| 200 mg/kg | 29.27 ± 0.75                                     | 31.04 ± 0.62                | 1.77 ± 0.32                 |
| 100 mg/kg | 29.41 ± 0.86                                     | 30.92 ± 1.17                | 1.51 ± 0.88                 |

Values are expressed mean ± SD of 10 mice, NH₄OH = Ammonia hydroxide, TB = Theobromine, AR = Adenophorae Radix (dried root parts of *Adenophora triphylla var. japonica* Hara) powders, KOG = *Kyeongok-go*, Traditional mixed herbal formulation, SKOG = *ShashamKyeongok-go*, KOG contains AR powders, Test material.

#### Table A2. Changes on the body weight gains in expectorant assay.

| Groups    | Body Weights (g) at Test Material Administration | Body Weight Gains (g) [B – A] |
|-----------|--------------------------------------------------|-----------------------------|
|           | First [A]                                        | Last [B]                    |                             |
| Controls  |                                                   |                             |                             |
| Intact    | 29.09 ± 1.23                                     | 30.96 ± 1.01                | 1.87 ± 0.60                 |
| Reference |                                                   |                             |                             |
| AM 250 mg/kg | 29.23 ± 1.16                                     | 31.22 ± 1.65                | 1.99 ± 0.73                 |
| AR 400 mg/kg| 29.40 ± 0.81                                     | 31.11 ± 1.25                | 1.71 ± 0.85                 |
| KOG 400 mg/kg| 29.00 ± 1.60                                    | 30.69 ± 1.77                | 1.69 ± 0.90                 |
| SKOG      |                                                   |                             |                             |
| 400 mg/kg | 29.26 ± 1.12                                     | 31.01 ± 1.76                | 1.75 ± 1.02                 |
| 200 mg/kg | 29.20 ± 1.26                                     | 31.25 ± 1.83                | 2.05 ± 0.92                 |
| 100 mg/kg | 29.18 ± 1.04                                     | 31.23 ± 1.76                | 2.05 ± 1.03                 |

Values are expressed mean ± SD of 10 mice, AM = Ambroxol, AR = Adenophorae Radix (dried root parts of *Adenophora triphylla var. japonica* Hara) powders, KOG = *Kyeongok-go*, Traditional mixed herbal formulation, SKOG = *ShashamKyeongok-go*, KOG contains AR powders, Test material.

#### Table A3. Changes on the body weight gains in anti-inflammatory assay.

| Groups    | Body Weights (g) at Test Material Administration | Body Weight Gains (g) [B – A] |
|-----------|--------------------------------------------------|-----------------------------|
|           | First [A]                                        | Last [B]                    |                             |
| Controls  |                                                   |                             |                             |
| Intact    | 28.94 ± 1.06                                     | 31.04 ± 1.49                | 2.10 ± 0.90                 |
| Xylene    | 28.93 ± 1.01                                     | 30.97 ± 1.62                | 2.04 ± 0.79                 |
| Reference |                                                   |                             |                             |
| DEXA 1 mg/kg | 28.72 ± 1.10                                     | 27.80 ± 1.66 eaf            | −0.92 ± 0.76 eaf            |
| AR 400 mg/kg| 28.99 ± 1.21                                     | 31.12 ± 2.51                | 2.13 ± 1.63                 |
| KOG 400 mg/kg| 29.20 ± 1.11                                    | 31.02 ± 1.78                | 1.82 ± 1.01                 |
| SKOG      |                                                   |                             |                             |
| 400 mg/kg | 29.11 ± 1.27                                     | 31.29 ± 2.19                | 2.18 ± 1.34                 |
| 200 mg/kg | 28.95 ± 1.26                                     | 31.29 ± 1.66                | 2.34 ± 0.70                 |
| 100 mg/kg | 29.07 ± 0.72                                     | 31.08 ± 1.10                | 2.01 ± 0.86                 |

Values are expressed mean ± SD of 10 mice, AR = Adenophorae Radix (dried root parts of *Adenophora triphylla var. japonica* Hara) powders, KOG = *Kyeongok-go*, Traditional mixed herbal formulation, SKOG = *ShashamKyeongok-go*, KOG contains AR powders, Test material. DEXA = Dexamethasone, eaf p < 0.01 as compared with intact control by LSD test, eaf p < 0.01 as compared with xylene control by LSD test.
28. Honda, H.; Fujimoto, M.; Miyamoto, S.; Ishikawa, N.; Serada, S.; Hattori, N.; Nomura, S.; Kohno, N.; Yokoyama, A.; Naka, T. Sputum leucine-rich alpha-2 glycoprotein as a marker of airway inflammation in asthma. PLoS ONE 2016, 11, e0162672. [CrossRef]

29. Lee, C.W.; Park, S.M.; Kim, Y.S.; Jegal, K.H.; Lee, J.R.; Cho, I.J.; Ku, S.K.; Lee, J.Y.; Ahn, Y.-T.; Son, Y. Biomolecular evidence of anti-inflammatory effects by Clematis mandshurica Ruprecht root extract in rodent cells. J. Ethnopharmacol. 2014, 155, 1141–1155. [CrossRef]

30. Saleem, M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett. 2009, 285, 109–115. [CrossRef]

31. Ibrahim, M.N.M.; Balakrishnan, R.B.S.; Shamsudeen, S.; Bahwani, S.A.; Adam, F. A concise review of the natural existence, synthesis, properties, and applications of syringaldehyde. Bioresources 2012, 7, 4377–4399. [CrossRef]

32. Shapla, U.M.; Solayman, M.; Alam, N.; Khalil, M.I.; Gan, S.H. 5-Hydroxymethyl furfural (HMF) levels in honey and other food products: Effects on bees and human health. Chem. Cent. J. 2018, 12, 35. [CrossRef] [PubMed]

33. Chao-Hsiang, C.; Yin-Shiou, L.I.N.; Chien, M.-Y.; Wen-Chi, H.O.U.; Miao-Lin, H.U. Antioxidant and antihypertensive activities of acteoside and its analogs. Bot. Stud. 2012, 53, 421–429.

34. Kim, S.-W.; Choi, S.-C.; Choi, E.-Y.; Kim, K.-S.; Oh, J.-M.; Lee, H.-J.; Oh, H.-M.; Kim, S.; Oh, B.-S.; Kimm, K.-C. Catalposide, a compound isolated from Catalpa ovata, attenuates induction of intestinal epithelial proinflammatory gene expression and reduces the severity of trinitrobenzene sulfonic acid-induced colitis in mice. Inflamm. Bowel Dis. 2004, 10, 564–572. [CrossRef] [PubMed]

35. Zhang, H.; Zhou, Z.; Chen, Z.; Zhong, Z.; Li, Z. Ginsenoside Rg3 exerts anti-depressive effect on an NMDA-treated cell model and a chronic mild stress animal model. J. Pharmacol. Sci. 2017, 134, 45–54. [CrossRef] [PubMed]

36. Horiiuchi, S.; Koshimizu, K. Biological Reference Data Book on Experimental Animals; Soft Science: Tokyo, Japan, 1989; p. 158.

37. Kim, H.-D.; Cho, K.-H.; Lee, B.-W.; Kwon, Y.-S.; Lee, H.-S.; Choi, S.-H.; Ku, S.-K. Effects of magnetic infrared laser irradiation on formalin-induced chronic paw inflammation of mice. J. Phys. Ther. Sci. 2010, 22, 395–404. [CrossRef]

38. Davey, M.G.; Hedrick, H.L.; Mendoza, J.M.; Kanai, M.; Adzick, N.S.; Flake, A.W. Pulmonary epithelial liquid absorption, expressed in relation to alveolar surface area, is reduced in fetal lambs following in utero tracheal occlusion. Pediatric Pulmonol. 2002, 34, 278–286. [CrossRef] [PubMed]

39. Tam, A.; Wadsworth, S.; Dorscheid, D.; Man, S.-F.P.; Sin, D.D. Estradiol increases mucus synthesis in bronchial epithelial cells. PLoS ONE 2014, 9, e100633. [CrossRef] [PubMed]

40. Kim, C.G.; Kang, M.; Lee, Y.-H.; Min, W.G.; Kim, Y.H.; Kang, S.J.; Song, C.H.; Park, S.J.; Park, J.H.; Han, C.H. Bathing effects of various seawaters on allergic (atopic) dermatitis-like skin lesions induced by 2, 4-dinitrochlorobenzene in hairless mice. Evid.-Based Complement. Altern. Med. 2015, 2015, 179185. [CrossRef]